Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis

Pharmacogenetics and Genomics

Volumn 20, Issue 10, 2010, Pages 619-629

  Kaspera, Rüdiger ^a   Naraharisetti, Suresh B ^a   Tamraz, Bani ^d   Sahele, Tariku ^a   Cheesman, Matthew J ^f   Kwok, Pui Yan ^d,e   Marciante, Kristin ^b   Heckbert, Susan R ^b,c   Psaty, Bruce M ^a,b,c   Totah, Rheem A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

CYP2C8 variants; CYP2C8*3; CYP2C8*4; nonfunctional variants; pharmacogenetics; promotor linkage disequilibrium

Indexed keywords

CERIVASTATIN; CYTOCHROME P450 2C8; GEMFIBROZIL;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CRYSTAL STRUCTURE; DRUG CLEARANCE; DRUG METABOLISM; ESCHERICHIA COLI; FRAMESHIFT MUTATION; GENE DELETION; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER; MAJOR CLINICAL STUDY; MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ESCHERICHIA COLI;

EID: 77957223834     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833ecace     Document Type: Article

References (40)

1. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112:71-105. (Pubitemid 44301483)
2. Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004; 292:2622-2631. (Pubitemid 39577518)
3. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346:539-540.
4. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 1999; 54:851-855. (Pubitemid 29051331)
5. Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000; 39:99-116.
6. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, et al. Metabolism of cerivastatin by human liver microsomes in vitrocharacterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 1997; 25:321-331. (Pubitemid 27120578)
7. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004; 34:961-971. (Pubitemid 40070099)
8. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72:685-691. (Pubitemid 36021007)
9. Baer BR, Delisle RK, Allen A. Benzylic oxidation of gemfibrozil-1-O- betaglucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem Res Toxicol 2009; 22:1298-1309.
10. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006; 34:191-197. (Pubitemid 43042661)
11. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77:341-352. (Pubitemid 40719263)
12. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607. (Pubitemid 32953585)
13. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002; 64:1579-1589. (Pubitemid 35333419)
14. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 2005; 33:630-636. (Pubitemid 40593876)
15. Ishikawa C, Ozaki H, Nakajima T, Ishii T, Kanai S, Anjo S, et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 2004; 49:582-585. (Pubitemid 39506542)
16. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62:162-172. (Pubitemid 34680528)
17. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. J Pharmacol Exp Ther 1997; 283:1552-1562. (Pubitemid 28016533)
18. Holmans PL, Shet MS, Martin-Wixtrom CA, Fisher CW, Estabrook RW. The high-level expression in Escherichia coli of the membrane-bound form of human and rat cytochrome b5 and studies on their mechanism of function. Arch Biochem Biophys 1994; 312:554-565. (Pubitemid 124007596)
19. Porter TD,Wilson TE, Kasper CB. Expression of a functional 78 000 dalton mammalian flavoprotein, NADPH-cytochrome P-450 oxidoreductase, in Escherichia coli. Arch Biochem Biophys 1987; 254:353-367.
20. Smith HE, Jones JP III, Kalhorn TF, Farin FM, Stapleton PL, Davis CL, et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitorinduced chronic kidney disease. Pharmacogenet Genomics 2008; 18:943-953.
21. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964; 239:2370-2378.
22. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150:76-85.
23. Nakano M, Kelly EJ, Rettie AE. Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase. Drug Metab Dispos 2009; 37:2119-2122.
24. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-1169. (Pubitemid 37414228)
25. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989. (Pubitemid 32289743)
26. Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009; 10:1489-1510.
27. Naraharisetti SB, Lin YS, Rieder M, Marciante K, Psaty BM, Thummel KE, et al. Human liver expression of CYP2C8: gender, age and genotype effects. Drug Metab Dispos 2010; 38:889-893.
28. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF. Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 2008; 283:17227-17237.
29. Rodriguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J 2008; 8:268-277. (Pubitemid 352038306)
30. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 2004; 279:9497-9503.
31. Marciante KD, Totah RA, Heckbert SR, Smith NL, Lemaitre RN, Lumley T, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics 2008; 18:535-543. (Pubitemid 351769921)
32. Ozaki H, Ishikawa CT, Ishii T, Toyoda A, Murano T, Miyashita Y, et al. Clearance rates of cerivastatin metabolites in a patient with cerivastatininduced rhabdomyolysis. J Clin Pharm Ther 2005; 30:189-192. (Pubitemid 41594456)
33. Ferguson SS, Chen Y, LeCluyse EL, Negishi M, Goldstein JA. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 2005; 68:747-757. (Pubitemid 41206028)
34. Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006; 80:657-667. (Pubitemid 44920222)
35. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003; 74:380-387. (Pubitemid 37222859)
36. Kirchheiner J, Meineke I, Fuhr U, Rodriguez-Antona C, Lebedeva E, Brockmoller J. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 2008; 9:277-288. (Pubitemid 351816765)
37. Soyama A, Hanioka N, Saito Y, Murayama N, Ando M, Ozawa S, et al. Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol Toxicol 2002; 91:174-178. (Pubitemid 35216919)
38. Soyama A, Saito Y, Hanioka N, Murayama N, Nakajima O, Katori N, et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 2001; 24:1427-1430. (Pubitemid 33133761)
39. Zhang H, Myshkin E, Waskell L. Role of cytochrome b5 in catalysis by cytochrome P450 2B4. Biochem Biophys Res Commun 2005; 338:499-506. (Pubitemid 41540596)
40. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transportermediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304:610-616. (Pubitemid 36152336)